# A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

> **NCT05028556** · PHASE1 · COMPLETED · sponsor: **Wuhan YZY Biopharma Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Metastatic or Locally Advanced Solid Tumors

## Interventions

- **DRUG:** Cohort 1 of Y101D
- **DRUG:** Cohort 2 of Y101D
- **DRUG:** Cohort 3 of Y101D
- **DRUG:** Cohort 4 of Y101D
- **DRUG:** Cohort 5 of Y101D

## Key facts

- **NCT ID:** NCT05028556
- **Lead sponsor:** Wuhan YZY Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2024-07-05
- **Final completion:** 2024-09-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028556, "A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05028556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*